Creating hydrogels to improve T cell therapies for cancer and autoimmune diseases
Lymph node inspired hydrogels for immune cell reprogramming
['FUNDING_R21'] · COLUMBIA UNIV NEW YORK MORNINGSIDE · NIH-11139785
This study is working on creating special gels that copy how lymph nodes work to help make T cell treatments for cancer and autoimmune diseases faster and cheaper, so more patients can get the care they need.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | COLUMBIA UNIV NEW YORK MORNINGSIDE (nih funded) |
| Locations | 1 site (NEW YORK, UNITED STATES) |
| Trial ID | NIH-11139785 on ClinicalTrials.gov |
What this research studies
This research focuses on developing innovative hydrogels that mimic the natural environment of lymph nodes to enhance the engineering of T cells for immunotherapy. By utilizing advanced techniques like DNA origami and colloidal science, the project aims to streamline the production of antigen-specific T cells, making the process more efficient and less costly. The goal is to overcome current challenges in T cell therapy, such as long production times and high costs, ultimately improving patient access to these treatments. Patients may benefit from more effective and affordable T cell therapies for conditions like cancer and autoimmune disorders.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancer or autoimmune disorders who may benefit from advanced T cell therapies.
Not a fit: Patients who do not have cancer or autoimmune conditions may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and accessible T cell therapies for patients with cancer and autoimmune diseases.
How similar studies have performed: Other research has shown promise in using biomimetic approaches to enhance T cell therapies, indicating potential for success in this novel approach.
Where this research is happening
NEW YORK, UNITED STATES
- COLUMBIA UNIV NEW YORK MORNINGSIDE — NEW YORK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CORREA, SANTIAGO — COLUMBIA UNIV NEW YORK MORNINGSIDE
- Study coordinator: CORREA, SANTIAGO
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer therapy